{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:16:36Z","timestamp":1790792196558,"version":"4.1.0"},"reference-count":236,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T00:00:00Z","timestamp":1700784000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.addr.2023.115146","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T06:40:10Z","timestamp":1701326410000},"page":"115146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Long-acting inhaled medicines: Present and future"],"prefix":"10.1016","volume":"204","author":[{"given":"Chengqian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"D'Angelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Buttini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3201-4696","authenticated-orcid":false,"given":"Mingshi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2023.115146_b0005","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1089\/jamp.2016.1297","article-title":"The history of therapeutic aerosols: a chronological review","volume":"30","author":"Stein","year":"2017","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2023.115146_b0010","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.apt.2019.10.013","article-title":"A particle technology approach toward designing dry-powder inhaler formulations for personalized medicine in respiratory diseases","volume":"31","author":"Kadota","year":"2020","journal-title":"Adv. Powder Technol."},{"key":"10.1016\/j.addr.2023.115146_b0015","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3132\/pcrj.2007.00017","article-title":"Inhalation therapy: an historical review","volume":"16","author":"Sanders","year":"2007","journal-title":"Prim. Care Respir. J."},{"key":"10.1016\/j.addr.2023.115146_b0020","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejpb.2021.04.003","article-title":"Oral inhalation for delivery of proteins and peptides to the lungs","volume":"163","author":"Fr\u00f6hlich","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2023.115146_b0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejim.2020.02.023","article-title":"Inhalation therapy devices for the treatment of obstructive lung diseases: the history of inhalers towards the ideal inhaler","volume":"75","author":"Sorino","year":"2020","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.addr.2023.115146_b0030","doi-asserted-by":"crossref","first-page":"180","DOI":"10.2174\/1567201815666181024143249","article-title":"Delivery of Dry Powders to the Lungs: Influence of Particle Attributes from a Biological and Technological Point of View","volume":"16","author":"Zellnitz","year":"2018","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.addr.2023.115146_b0035","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1080\/02786829408959755","article-title":"Medical aerosol inhalers: Past, present, and future","volume":"22","author":"Clark","year":"1995","journal-title":"Aerosol Sci. Tech."},{"key":"10.1016\/j.addr.2023.115146_b0040","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ijpharm.2018.07.008","article-title":"Challenges for pulmonary delivery of high powder doses","volume":"548","author":"Sibum","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2023.115146_b0045","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1016\/j.apsb.2021.05.015","article-title":"Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines","volume":"11","author":"Guo","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.addr.2023.115146_b0050","article-title":"Inhaled Therapy in Respiratory Disease: The Complex Interplay of Pulmonary Kinetic Processes","volume":"2018","author":"Borghardt","year":"2018","journal-title":"Can. Respir. J."},{"key":"10.1016\/j.addr.2023.115146_b0055","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1136\/qhc.11.4.376","article-title":"Inhaler devices for the treatment of asthma and chronic obstructive airways disease (COPD)","volume":"11","author":"Wright","year":"2002","journal-title":"Qual. Saf. Health Care"},{"key":"10.1016\/j.addr.2023.115146_b0060","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/j.2042-7158.2012.01486.x","article-title":"Engineered PLGA nano- and micro-carriers for pulmonary delivery: Challenges and promises","volume":"64","author":"Ungaro","year":"2012","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.addr.2023.115146_b0065","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijpharm.2013.04.077","article-title":"Development of a pulmonary peptide delivery system using porous nanoparticle-aggregate particles for systemic application","volume":"451","author":"Yang","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2023.115146_b0070","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jconrel.2020.03.019","article-title":"Enhanced pulmonary systemic delivery of protein drugs via zwitterionic polymer conjugation","volume":"322","author":"Tsao","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115146_b0075","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1016\/j.ddtec.2011.12.003","article-title":"Formulation technologies to overcome unfavorable properties of peptides and proteins for pulmonary delivery","volume":"9","author":"Wan","year":"2012","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.addr.2023.115146_b0080","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1136\/oem.37.4.337","article-title":"Deposition, retention, and clearance of inhaled particles","volume":"37","author":"Lippmann","year":"1980","journal-title":"Occup. Environ. Med."},{"key":"10.1016\/j.addr.2023.115146_b0085","doi-asserted-by":"crossref","unstructured":"S. Muranishi, T. Fujita, M. Murakami, A. Yamamoto, Potential for lymphatic targeting of peptides, 1997.","DOI":"10.1016\/S0168-3659(96)01588-X"},{"key":"10.1016\/j.addr.2023.115146_b0090","first-page":"402","article-title":"Pulmonary drug delivery: From generating aerosols to overcoming biological barriers-therapeutic possibilities and technological challenges, Lancet","volume":"1","author":"Ruge","year":"2013","journal-title":"Respir. Med."},{"key":"10.1016\/j.addr.2023.115146_b0095","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.medengphy.2011.12.025","article-title":"Developing an efficient and reliable dry powder inhaler for pulmonary drug delivery - A review for multidisciplinary researchers","volume":"34","author":"Islam","year":"2012","journal-title":"Med. Eng. Phys."},{"key":"10.1016\/j.addr.2023.115146_b0100","first-page":"56","article-title":"Geometry and Dimensions of Airways of the Respiratory Zone, Morphometry of the Human","author":"Weibel","year":"1963","journal-title":"Lung"},{"key":"10.1016\/j.addr.2023.115146_b0105","first-page":"2","article-title":"Dry powder inhalers and the right things to remember: A concept review, Multidiscip","volume":"10","author":"Dal Negro","year":"2015","journal-title":"Respir. Med."},{"key":"10.1016\/j.addr.2023.115146_b0110","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.addr.2005.07.001","article-title":"The basics and underlying mechanisms of mucoadhesion","volume":"57","author":"Smart","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2023.115146_b0115","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1166\/jbn.2017.2326","article-title":"Curcumin acetate nanocrystals for sustained pulmonary delivery: Preparation, characterization and in vivo evaluation","volume":"13","author":"Hu","year":"2017","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.addr.2023.115146_b0120","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1398-9995.2006.01090.x","article-title":"Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma","volume":"61","author":"Buhl","year":"2006","journal-title":"Allergy"},{"key":"10.1016\/j.addr.2023.115146_b0125","doi-asserted-by":"crossref","unstructured":"J.A. Champion, S. Mitragotri, Role of target geometry in phagocytosis, Proceedings of the National Academy of Sciences. 103 (2006) 4930\u20134934. https:\/\/doi.org\/10.1073\/pnas.0600997103.","DOI":"10.1073\/pnas.0600997103"},{"key":"10.1016\/j.addr.2023.115146_b0130","doi-asserted-by":"crossref","DOI":"10.1089\/jamp.2009.0797","article-title":"Update on macrophage clearance of inhaled micro- and nanoparticles","volume":"23","author":"Geiser","year":"2010","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2023.115146_b0135","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/jemt.10105","article-title":"Morphological aspects of particle uptake by lung phagocytes","volume":"57","author":"Geiser","year":"2002","journal-title":"Microsc. Res. Tech."},{"key":"10.1016\/j.addr.2023.115146_b0140","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.addr.2014.05.014","article-title":"Carrier interactions with the biological barriers of the lung: Advanced in vitro models and challenges for pulmonary drug delivery","volume":"75","author":"de Souza Carvalho","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2023.115146_b0145","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.addr.2007.08.023","article-title":"In vivo animal models for drug delivery across the lung mucosal barrier","volume":"59","author":"Cryan","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2023.115146_b0150","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ijpharm.2018.07.050","article-title":"Pharmacokinetics and pharmacodynamics of high doses of inhaled dry powder drugs","volume":"549","author":"Kukut Hatipoglu","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2023.115146_b0155","doi-asserted-by":"crossref","first-page":"C1777","DOI":"10.1152\/ajpcell.00181.2022","article-title":"The underappreciated role of resident epithelial cell populations in metastatic progression: contributions of the lung alveolar epithelium","volume":"323","author":"Christenson","year":"2022","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.addr.2023.115146_b0160","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S1773-2247(13)50052-9","article-title":"Particle engineering technologies for improving the delivery of peptide and protein drugs","volume":"23","author":"Wan","year":"2013","journal-title":"J Drug Deliv Sci Technol."},{"key":"10.1016\/j.addr.2023.115146_b0165","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.addr.2021.04.006","article-title":"Particle engineering principles and technologies for pharmaceutical biologics","volume":"174","author":"Cun","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2023.115146_b0170","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/2040622313518227","article-title":"Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases","volume":"5","author":"Alagha","year":"2014","journal-title":"Ther Adv Chronic Dis."},{"key":"10.1016\/j.addr.2023.115146_b0175","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1586\/17512433.2015.1058154","article-title":"Long-acting muscarinic antagonists","volume":"8","author":"Melani","year":"2015","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2023.115146_b0180","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/BF02718123","article-title":"The pharmacology of salmeterol","volume":"168","author":"Johnson","year":"1990","journal-title":"Lung"},{"key":"10.1016\/j.addr.2023.115146_b0185","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2147\/COPD.S1353","article-title":"Long-acting \u03b22-agonists (LABA) in chronic obstructive pulmonary disease: Efficacy and safety","volume":"3","author":"Rossi","year":"2008","journal-title":"Int. J. COPD"},{"key":"10.1016\/j.addr.2023.115146_b0190","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1136\/thx.48.2.148","article-title":"Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients","volume":"48","author":"Lundback","year":"1993","journal-title":"Thorax"},{"key":"10.1016\/j.addr.2023.115146_b0195","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1016\/0024-3205(93)90729-M","article-title":"Formoterol: Pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective \u03b22-adrenoceptor agonist bronchodilator","volume":"52","author":"Anderson","year":"1993","journal-title":"Life Sci."},{"key":"10.1016\/j.addr.2023.115146_b0200","doi-asserted-by":"crossref","unstructured":"J. L\u00f6tvall, Pharmacological similarities and differences between beta2-agonists, Respir Med. 95 Suppl B (2001). https:\/\/doi.org\/10.1053\/rmed.2001.1139.","DOI":"10.1053\/rmed.2001.1139"},{"key":"10.1016\/j.addr.2023.115146_b0205","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nrd2153","article-title":"Inhaling medicines: Delivering drugs to the body through the lungs","volume":"6","author":"Patton","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2023.115146_b0210","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1002\/jps.21380","article-title":"Fluticasone and budesonide nanosuspensions for pulmonary delivery: Preparation, characterization, and pharmacokinetic studies","volume":"97","author":"Yang","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2023.115146_b0215","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.pupt.2007.08.005","article-title":"Do airway clearance mechanisms influence the local and systemic effects of inhaled corticosteroids?","volume":"21","author":"Edsb\u00e4cker","year":"2008","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2023.115146_b0220","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0954-6111(95)90259-7","article-title":"Fluticasone propionate - an update on preclinical and clinical experience","volume":"89","author":"Fuller","year":"1995","journal-title":"Respir. Med."},{"key":"10.1016\/j.addr.2023.115146_b0225","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40262-012-0021-x","article-title":"Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate","volume":"52","author":"Allen","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.addr.2023.115146_b0230","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/bcp.12637","article-title":"Inhaled corticosteroids: Potency, dose equivalence and therapeutic index","volume":"80","author":"Daley-Yates","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2023.115146_b0235","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s11095-015-1808-x","article-title":"Sustained Pulmonary Delivery of a Water-Soluble Antibiotic Without Encapsulating Carriers","volume":"33","author":"Ong","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2023.115146_b0240","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1124\/jpet.117.242099","article-title":"Preclinical pharmacology and pharmacokinetics of inhaled hexadecyl-treprostinil (C16TR), a pulmonary vasodilator prodrug","volume":"363","author":"Corboz","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.addr.2023.115146_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2021.102002","article-title":"An overview of the biology of a long-acting inhaled treprostinil prodrug","volume":"65","author":"Chapman","year":"2020","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2023.115146_b0250","doi-asserted-by":"crossref","first-page":"9802","DOI":"10.1021\/acs.jmedchem.2c00416","article-title":"Design, Synthesis, and Evaluation of Lung-Retentive Prodrugs for Extending the Lung Tissue Retention of Inhaled Drugs","volume":"65","author":"Ayre","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2023.115146_b0255","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14020302","article-title":"Strategies to Overcome Biological Barriers Associated with Pulmonary Drug Delivery","volume":"14","author":"Plaunt","year":"2022","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.addr.2023.115146_b0260","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-07698-6","article-title":"Inhalation of the prodrug PI3K inhibitor CL27c improves lung function in asthma and fibrosis","volume":"9","author":"Campa","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2023.115146_b0265","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/17425255.2021.1908262","article-title":"Drug metabolism in the lungs: opportunities for optimising inhaled medicines","volume":"17","author":"Enlo-Scott","year":"2021","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.addr.2023.115146_b0270","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejpb.2021.04.025","article-title":"Recent advances in prodrug-based nanoparticle therapeutics","volume":"165","author":"Chen","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2023.115146_b0275","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, Patients with Pulmonary Arterial Hypertension A Double-blind, Randomized, Placebo-controlled Trial","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2023.115146_b0280","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1055\/s-0044-100374","article-title":"Inhaled Treprostinil-Prodrug Lipid Nanoparticle Formulations Provide Long-Acting Pulmonary Vasodilation","volume":"68","author":"Leifer","year":"2018","journal-title":"Drug Res."},{"key":"10.1016\/j.addr.2023.115146_b0285","first-page":"18","article-title":"Polymer-drug conjugates as inhalable drug delivery systems: A review, Curr Opin Colloid","volume":"31","author":"Marasini","year":"2017","journal-title":"Interface Sci."},{"key":"10.1016\/j.addr.2023.115146_b0290","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.addr.2014.05.017","article-title":"Delivery strategies for sustained drug release in the lungs","volume":"75","author":"Loira-Pastoriza","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2023.115146_b0295","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jconrel.2013.07.023","article-title":"Polyethylene glycol-drug ester conjugates for prolonged retention of small inhaled drugs in the lung","volume":"171","author":"Bayard","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115146_b0300","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ijpharm.2010.07.030","article-title":"In vivo efficacy of dendrimer-methylprednisolone conjugate formulation for the treatment of lung inflammation","volume":"399","author":"Inapagolla","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2023.115146_b0305","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ijpharm.2009.10.017","article-title":"Drug release characteristics of PAMAM dendrimer\u2013drug conjugates with different linkers","volume":"384","author":"Kurtoglu","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2023.115146_b0310","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ijpharm.2010.03.058","article-title":"Pulmonary delivery of cisplatin-hyaluronan conjugates via endotracheal instillation for the treatment of lung cancer","volume":"392","author":"Xie","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2023.115146_b0315","doi-asserted-by":"crossref","unstructured":"M. Rudokas, M. Najlah, M.A. Alhnan, A. Elhissi, Liposome Delivery Systems for Inhalation: A Critical Review Highlighting Formulation Issues and Anticancer Applications, in: Medical Principles and Practice, S. Karger AG, 2016: pp. 60\u201372. https:\/\/doi.org\/10.1159\/000445116.","DOI":"10.1159\/000445116"},{"key":"10.1016\/j.addr.2023.115146_b0330","doi-asserted-by":"crossref","unstructured":"S. Bhatia, Natural Polymers vs Synthetic Polymer, in: Natural Polymer Drug Delivery Systems, Springer International Publishing, 2016: pp. 95\u2013118. https:\/\/doi.org\/10.1007\/978-3-319-41129-3_3.","DOI":"10.1007\/978-3-319-41129-3_3"},{"key":"10.1016\/j.addr.2023.115146_b0335","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jconrel.2020.01.028","article-title":"Polyester based polymeric nano and microparticles for pharmaceutical purposes: A review on formulation approaches","volume":"320","author":"Molavi","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115146_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119441","article-title":"Quality by design thinking in the development of long-acting injectable PLGA\/PLA-based microspheres for peptide and protein drug delivery","volume":"585","author":"Zhang","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2023.115146_b0345","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","article-title":"PLGA-based nanoparticles: An overview of biomedical applications","volume":"161","author":"Danhier","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115146_b0350","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.3390\/molecules25061311","article-title":"Design and Characterizations of Inhalable Poly(lactic-co-glycolic acid) Microspheres Prepared by the Fine Droplet Drying Process for a Sustained Effect of Salmon Calcitonin","volume":"25","author":"Sato","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.addr.2023.115146_b0355","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ijpharm.2011.05.007","article-title":"Formulation and in vitro characterization of inhalable rifampicin-loaded PLGA microspheres for sustained lung delivery","volume":"414","author":"Doan","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2023.115146_b0360","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ejps.2016.08.024","article-title":"Pulmonary pharmacokinetics of levofloxacin in rats after aerosolization of immediate-release chitosan or sustained-release PLGA microspheres","volume":"93","author":"Gaspar","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2023.115146_b0365","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.actbio.2020.12.061","article-title":"Inhalable PLGA microspheres: Tunable lung retention and systemic exposure via polyethylene glycol modification","volume":"123","author":"Li","year":"2021","journal-title":"Acta Biomater."},{"key":"10.1016\/j.addr.2023.115146_b0370","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2004.01.044","article-title":"Poly-\u03b5-caprolactone microspheres and nanospheres: An overview","volume":"278","author":"Sinha","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2023.115146_b0375","article-title":"Natural Fiber-Reinforced Polycaprolactone Green and Hybrid Biocomposites for Various Advanced Applications","volume":"14","author":"Ilyas","year":"2022","journal-title":"Polymers (basel)."},{"key":"10.1016\/j.addr.2023.115146_b0380","doi-asserted-by":"crossref","first-page":"13587","DOI":"10.1021\/acsami.9b19715","article-title":"A Synergistic Relationship between Polycaprolactone and Natural Polymers Enhances the Physical Properties and Biological Activity of Scaffolds","volume":"12","author":"Sawadkar","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.addr.2023.115146_b0385","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0168-3659(03)00367-5","article-title":"Effects of crystalline microstructure on drug release behavior of poly(\u03b5-caprolactone) microspheres","volume":"92","author":"Jeong","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115146_b0390","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.powtec.2014.03.011","article-title":"Polymeric controlled release inhalable powder produced by vibrational spray-drying: One-step preparation and in vitro lung deposition","volume":"258","author":"Fontana","year":"2014","journal-title":"Powder Technol."},{"key":"10.1016\/j.addr.2023.115146_b0395","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jddst.2015.07.008","article-title":"Inhalable resveratrol microparticles produced by vibrational atomization spray drying for treating pulmonary arterial hypertension","volume":"29","author":"Dimer","year":"2015","journal-title":"J Drug Deliv Sci Technol."},{"key":"10.1016\/j.addr.2023.115146_b0400","first-page":"1","volume":"2","author":"Yang","year":"2007","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2023.115146_b0405","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ijpharm.2018.05.060","article-title":"Development of ciprofloxacin-loaded poly(vinyl alcohol) dry powder formulations for lung delivery","volume":"547","author":"Silva","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2023.115146_b0410","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejpb.2012.12.003","article-title":"Correlation of drug release with pulmonary drug absorption profiles for nebulizable liposomal formulations","volume":"84","author":"Beck-Broichsitter","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2023.115146_b0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jps.21423","article-title":"Colloidal soft matter as drug delivery system","volume":"98","author":"Bonacucina","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2023.115146_b0420","first-page":"1139","article-title":"Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery","volume":"7","author":"Chen","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.addr.2023.115146_b0425","unstructured":"European Medicines Agency, Assessment report, Arikayce liposomal, (2020). https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/arikayce-liposomal-epar-public-assessment-report_en.pdf (accessed November 4, 2023)."},{"key":"10.1016\/j.addr.2023.115146_b0430","unstructured":"ARIKAYCE targets the MAC infection directly in your lungs, (n.d.). https:\/\/www.arikayce.com\/why-arikayce\/how-arikayce-works\/ (accessed November 4, 2023)."},{"key":"10.1016\/j.addr.2023.115146_b0435","doi-asserted-by":"crossref","first-page":"331","DOI":"10.4103\/0970-2113.159559","article-title":"A novel approach for lung delivery of rifampicin-loaded liposomes in dry powder form for the treatment of tuberculosis","volume":"32","author":"Patil","year":"2015","journal-title":"Lung India"},{"key":"10.1016\/j.addr.2023.115146_b0440","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4103\/1735-5362.235156","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: Applications, advantages and disadvantages","volume":"13","author":"Ghasemiyeh","year":"2018","journal-title":"Res Pharm Sci."},{"key":"10.1016\/j.addr.2023.115146_b0445","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ijpharm.2016.11.046","article-title":"Solid lipid nanoparticles for sustained pulmonary delivery of Yuxingcao essential oil: Preparation, characterization and in vivo evaluation","volume":"516","author":"Zhao","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2023.115146_b0450","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ijpharm.2016.01.080","article-title":"Pulmonary targeting potential of rosuvastatin loaded nanostructured lipid carrier: Optimization by factorial design","volume":"501","author":"Patil-Gadhe","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2023.115146_b0455","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jconrel.2013.04.018","article-title":"Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA","volume":"171","author":"Taratula","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115146_b0460","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ejps.2018.10.003","article-title":"Nanostructured lipid carriers versus solid lipid nanoparticles for the potential treatment of pulmonary hypertension via nebulization","volume":"125","author":"Nafee","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2023.115146_b0465","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejpb.2013.08.013","article-title":"Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: A review of the state of the art","volume":"86","author":"Weber","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2023.115146_b0470","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejpb.2006.07.006","article-title":"Solid lipid microparticles as a sustained release system for pulmonary drug delivery","volume":"65","author":"Jaspart","year":"2007","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2023.115146_b0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121046","article-title":"Inhalable bedaquiline-loaded cubosomes for the treatment of non-small cell lung cancer (NSCLC)","volume":"607","author":"Patil","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2023.115146_b0480","doi-asserted-by":"crossref","unstructured":"A.K. Thakur, B. Kaundle, I. Singh, Mucoadhesive drug delivery systems in respiratory diseases, in: Targeting Chronic Inflammatory Lung Diseases Using Advanced Drug Delivery Systems, Elsevier, 2020: pp. 475\u2013491. https:\/\/doi.org\/10.1016\/B978-0-12-820658-4.00022-4.","DOI":"10.1016\/B978-0-12-820658-4.00022-4"},{"key":"10.1016\/j.addr.2023.115146_b0485","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004294","article-title":"Altering mucus rheology to \u201csolidify\u201d human mucus at the nanoscale","volume":"4","author":"Lai","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2023.115146_b0490","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/md18120605","article-title":"The Application of Mucoadhesive Chitosan Nanoparticles in Nasal Drug Delivery","volume":"18","author":"Shim","year":"2020","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.addr.2023.115146_b0495","article-title":"Chitosan Nanoparticle-Based System: A New Insight into the Promising Controlled Release System for Lung Cancer Treatment","volume":"27","author":"Kuen","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.addr.2023.115146_b0500","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1211\/jpp.58.8.0002","article-title":"Advances and potential applications of chitosan derivatives as mucoadhesive biomaterials in modern drug delivery","volume":"58","author":"Chopra","year":"2010","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.addr.2023.115146_b0505","doi-asserted-by":"crossref","first-page":"14341","DOI":"10.1039\/C6NR03256G","article-title":"Recent advances in chitosan-based nanoparticulate pulmonary drug delivery","volume":"8","author":"Islam","year":"2016","journal-title":"Nanoscale"},{"key":"10.1016\/j.addr.2023.115146_b0510","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejps.2016.12.013","article-title":"Nanocrystals embedded in chitosan-based respirable swellable microparticles as dry powder for sustained pulmonary drug delivery","volume":"99","author":"Ni","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2023.115146_b0515","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jconrel.2018.05.031","article-title":"Sustained therapeutic efficacy of budesonide-loaded chitosan swellable microparticles after lung delivery: Influence of in vitro release, treatment interval and dose","volume":"283","author":"Zhang","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115146_b0520","first-page":"2975","article-title":"Long-acting inhalable chitosan-coated poly(lactic-co-glycolic acid) nanoparticles containing hydrophobically modified exendin-4 for treating type 2 diabetes","volume":"8","author":"Lee","year":"2013","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.addr.2023.115146_b0525","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ejps.2012.05.016","article-title":"Design and evaluation of inhalable chitosan-modified poly (dl-lactic-co-glycolic acid) nanocomposite particles","volume":"47","author":"Yang","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2023.115146_b0530","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.ijbiomac.2019.11.066","article-title":"Hyaluronic acid: A review on its biology, aspects of drug delivery, route of administrations and a special emphasis on its approved marketed products and recent clinical studies","volume":"151","author":"Vasvani","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.addr.2023.115146_b0535","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/1753465812458984","article-title":"Nebulized hypertonic saline containing hyaluronic acid improves tolerability in patients with cystic fibrosis and lung disease compared with nebulized hypertonic saline alone: A prospective, randomized, double-blind, controlled study","volume":"6","author":"Furnari","year":"2012","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.addr.2023.115146_b0540","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijpharm.2016.12.002","article-title":"Engineered sodium hyaluronate respirable dry powders for pulmonary drug delivery","volume":"517","author":"Martinelli","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2023.115146_b0545","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0168-3659(03)00263-3","article-title":"Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs","volume":"91","author":"Surendrakumar","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115146_b0550","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11050203","article-title":"Sodium hyaluronate nanocomposite respirable microparticles to tackle antibiotic resistance with potential application in treatment of mycobacterial pulmonary infections","volume":"11","author":"Rossi","year":"2019","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.addr.2023.115146_b0555","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.carbpol.2017.05.020","article-title":"Inhaled hyaluronic acid microparticles extended pulmonary retention and suppressed systemic exposure of a short-acting bronchodilator","volume":"172","author":"Li","year":"2017","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.addr.2023.115146_b0560","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.carbpol.2017.11.018","article-title":"Budesonide nanocrystal-loaded hyaluronic acid microparticles for inhalation: In vitro and in vivo evaluation","volume":"181","author":"Liu","year":"2018","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.addr.2023.115146_b0565","doi-asserted-by":"crossref","unstructured":"M. Sakagami, K. Sakon, W. Kinoshita, Y. Makino, Enhanced pulmonary absorption following aerosol administration of mucoadhesive powder microspheres, 2001. www.elsevier.com\/locate\/jconrel.","DOI":"10.1016\/S0168-3659(01)00475-8"},{"key":"10.1016\/j.addr.2023.115146_b0570","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0168-3659(02)00034-2","article-title":"Mucoadhesive beclomethasone microspheres for powder inhalation: Their pharmacokinetics and pharmacodynamics evaluation","volume":"80","author":"Sakagami","year":"2002","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115146_b0575","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1601556","article-title":"Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation","volume":"3","author":"Schneider","year":"2017","journal-title":"Sci. Adv."},{"key":"10.1016\/j.addr.2023.115146_b0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122661","article-title":"Airway mucus in pulmonary diseases: Muco-adhesive and muco-penetrating particles to overcome the airway mucus barriers","volume":"634","author":"Pangeni","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2023.115146_b0585","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.addr.2008.11.002","article-title":"Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues","volume":"61","author":"Lai","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2023.115146_b0590","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/17425247.2021.1854222","article-title":"Enhancing nanoparticle penetration through airway mucus to improve drug delivery efficacy in the lung","volume":"18","author":"Chen","year":"2021","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2023.115146_b0595","first-page":"157","article-title":"Overcoming the pulmonary barrier: New insights to improve the efficiency of inhaled therapeutics, Eur","volume":"6","author":"Murgia","year":"2014","journal-title":"J Nanomed."},{"key":"10.1016\/j.addr.2023.115146_b0600","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40348-016-0044-8","article-title":"Inhaled protein\/peptide-based therapies for respiratory disease","volume":"3","author":"Fellner","year":"2016","journal-title":"Mol Cell Pediatr."},{"key":"10.1016\/j.addr.2023.115146_b0605","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3390\/pharmaceutics6020333","article-title":"Inhalable PEGylated phospholipid nanocarriers and PEGylated therapeutics for respiratory delivery as aerosolized colloidal dispersions and dry powder inhalers","volume":"6","author":"Muralidharan","year":"2014","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.addr.2023.115146_b0610","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ijpharm.2016.02.031","article-title":"Enhanced pulmonary delivery of fluticasone propionate in rodents by mucus-penetrating nanoparticles","volume":"502","author":"Popov","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2023.115146_b0615","doi-asserted-by":"crossref","DOI":"10.1007\/s13346-023-01351-6","article-title":"Engineered lipid liquid crystalline nanoparticles as an inhaled nanoplatform for mucus penetration enhancement","author":"Wang","year":"2023","journal-title":"Drug Deliv. Transl. Res."},{"issue":"1997","key":"10.1016\/j.addr.2023.115146_b0620","first-page":"1868","article-title":"Large porous particles for pulmonary drug delivery","volume":"276","author":"Edwards","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.addr.2023.115146_b0625","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1023\/A:1018910200420","article-title":"Formulation and physical characterization of large porous particles for inhalation","volume":"16","author":"Vanbever","year":"1999","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2023.115146_b0630","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejpb.2012.01.018","article-title":"Zinc-alginate microparticles for controlled pulmonary delivery of proteins prepared by spray-drying","volume":"81","author":"M\u00f6bus","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2023.115146_b0635","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1021\/acs.biomac.5b01646","article-title":"Large Porous Particles for Sustained Release of a Decoy Oligonucelotide and Poly(ethylenimine): Potential for Combined Therapy of Chronic Pseudomonas aeruginosa Lung Infections","volume":"17","author":"D\u2019Angelo","year":"2016","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.addr.2023.115146_b0640","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/j.biomaterials.2008.12.044","article-title":"Development of highly porous large PLGA microparticles for pulmonary drug delivery","volume":"30","author":"Yang","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2023.115146_b0645","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1016\/j.biomaterials.2012.04.018","article-title":"Doxorubicin-loaded highly porous large PLGA microparticles as a sustained- release inhalation system for the treatment of metastatic lung cancer","volume":"33","author":"Kim","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2023.115146_b0650","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jconrel.2017.01.023","article-title":"Exploring polyvinylpyrrolidone in the engineering of large porous PLGA microparticles via single emulsion method with tunable sustained release in the lung: In vitro and in vivo characterization","volume":"249","author":"Ni","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115146_b0655","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejpb.2020.08.021","article-title":"Engineering large porous microparticles with tailored porosity and sustained drug release behavior for inhalation","volume":"155","author":"Zhang","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2023.115146_b0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120320","article-title":"Formulation and optimization of sildenafil citrate-loaded PLGA large porous microparticles using spray freeze-drying technique: A factorial design and in-vivo pharmacokinetic study","volume":"597","author":"Shahin","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2023.115146_b0665","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.tibtech.2007.09.005","article-title":"Nanoparticles for drug delivery to the lungs","volume":"25","author":"Sung","year":"2007","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.addr.2023.115146_b0670","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/394507","article-title":"The transport and deposition of nanoparticles in respiratory system by inhalation","volume":"2015","author":"Qiao","year":"2015","journal-title":"J. Nanomater."},{"key":"10.1016\/j.addr.2023.115146_b0675","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejpb.2017.08.001","article-title":"Inhalable siRNA-loaded nano-embedded microparticles engineered using microfluidics and spray drying","volume":"120","author":"Agnoletti","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2023.115146_b0680","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2019.105028","article-title":"Sustained-release microparticle dry powders of chloramphenicol palmitate or thiamphenicol palmitate prodrugs for lung delivery as aerosols","volume":"138","author":"Nurbaeti","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2023.115146_b0685","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.colsurfb.2009.02.001","article-title":"Preparation and properties of inhalable nanocomposite particles for treatment of lung cancer","volume":"71","author":"Tomoda","year":"2009","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.addr.2023.115146_b0690","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13111825","article-title":"Inhalable microparticles embedding calcium phosphate nanoparticles for heart targeting: The formulation experimental design","volume":"13","author":"Quarta","year":"2021","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.addr.2023.115146_b0695","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2217\/nnm.12.125","article-title":"Functional interaction between charged nanoparticles and cardiac tissue: A new paradigm for cardiac arrhythmia?","volume":"8","author":"Miragoli","year":"2013","journal-title":"Nanomedicine"},{"key":"10.1016\/j.addr.2023.115146_b0700","doi-asserted-by":"crossref","first-page":"6205","DOI":"10.1126\/scitranslmed.aan6205","article-title":"Inhalation of peptide-loaded nanoparticles improves heart failure","volume":"10","author":"Miragoli","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2023.115146_b0705","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.colsurfb.2015.12.017","article-title":"Disintegration of nano-embedded microparticles after deposition on mucus: A mechanistic study","volume":"139","author":"Ruge","year":"2016","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.addr.2023.115146_b0710","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ejps.2012.02.024","article-title":"Design and evaluation of poly(dl-lactic-co-glycolic acid) nanocomposite particles containing salmon calcitonin for inhalation","volume":"46","author":"Yang","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2023.115146_b0715","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.peptides.2012.03.021","article-title":"Inhalable sustained-release formulation of long-acting vasoactive intestinal peptide derivative alleviates acute airway inflammation","volume":"35","author":"Onoue","year":"2012","journal-title":"Peptides (n.y.)"},{"key":"10.1016\/j.addr.2023.115146_b0720","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s11095-011-0379-8","article-title":"Inhalable sustained-release formulation of glucagon: In vitro amyloidogenic and inhalation properties, and in vivo absorption and bioactivity","volume":"28","author":"Onoue","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2023.115146_b0725","doi-asserted-by":"crossref","unstructured":"R.A. Lazarus, J.S. Wagener, Recombinant human deoxyribonuclease I, in: Pharmaceutical Biotechnology: Fundamentals and Applications, Springer International Publishing, 2019: pp. 471\u2013488. https:\/\/doi.org\/10.1007\/978-3-030-00710-2_22.","DOI":"10.1007\/978-3-030-00710-2_22"},{"key":"10.1016\/j.addr.2023.115146_b0730","unstructured":"The Antibody Society., Therapeutic monoclonal antibodies approved or in regulatory review., (2023). www.antibodysociety.org\/antibody-therapeutics-product- date."},{"key":"10.1016\/j.addr.2023.115146_b0735","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1007\/s00253-021-11488-4","article-title":"Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections","volume":"105","author":"Parray","year":"2021","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.addr.2023.115146_b0740","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jconrel.2014.10.003","article-title":"Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system","volume":"196","author":"Guilleminault","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115146_b0745","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00281-009-0160-9","article-title":"Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn","volume":"31","author":"Baker","year":"2009","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.addr.2023.115146_b0750","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.4161\/mabs.34454","article-title":"VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with k-ras activating-mutations","volume":"6","author":"Herv\u00e9","year":"2014","journal-title":"MAbs"},{"key":"10.1016\/j.addr.2023.115146_b0755","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/19420862.2018.1556081","article-title":"Exploring the fate of inhaled monoclonal antibody in the lung parenchyma by microdialysis","volume":"11","author":"Guillon","year":"2019","journal-title":"MAbs"},{"key":"10.1016\/j.addr.2023.115146_b0760","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00063030-200923020-00003","article-title":"Strategies to extend plasma half-lives of recombinant antibodies","volume":"23","author":"Kontermann","year":"2009","journal-title":"BioDrugs"},{"key":"10.1016\/j.addr.2023.115146_b0765","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.xphs.2019.05.031","article-title":"Considerations for the Design of Antibody-Based Therapeutics","volume":"109","author":"Goulet","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2023.115146_b0770","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24213835","article-title":"Multimerization through pegylation improves pharmacokinetic properties of scFv fragments of GD2-specific antibodies","volume":"24","author":"Kholodenko","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.addr.2023.115146_b0775","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1111385","article-title":"Avidity engineering of human heavy-chain-only antibodies mitigates neutralization resistance of SARS-CoV-2 variants","volume":"14","author":"Du","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2023.115146_b0780","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jconrel.2014.05.021","article-title":"PEGylation of antibody fragments greatly increases their local residence time following delivery to the respiratory tract","volume":"187","author":"Koussoroplis","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115146_b0785","doi-asserted-by":"crossref","unstructured":"A.P. Chapman, PEGylated antibodies and antibody fragments for improved therapy: a review, 2002. www.elsevier.com\/locate\/drugdeliv.","DOI":"10.1016\/S0169-409X(02)00026-1"},{"key":"10.1016\/j.addr.2023.115146_b0790","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1006\/cyto.2001.0936","article-title":"Adapting Pharmacokinetic Properties of a Humanized Anti-Interleukin-8 Antibody for Therapeutic Applications Using Site-Specific PEGylation","volume":"16","author":"Leong","year":"2001","journal-title":"Cytokine"},{"key":"10.1016\/j.addr.2023.115146_b0795","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ijpharm.2017.02.021","article-title":"PEGylation prolongs the pulmonary retention of an anti-IL-17A Fab\u2019 antibody fragment after pulmonary delivery in three different species","volume":"521","author":"Freches","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2023.115146_b0800","doi-asserted-by":"crossref","first-page":"23514","DOI":"10.1074\/jbc.M604292200","article-title":"Properties of Human IgG1s engineered for enhanced binding to the neonatal Fc Receptor (FcRn)","volume":"281","author":"Dall\u2019Acqua","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2023.115146_b0805","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1021\/bc700319r","article-title":"Modulation of antibody pharmacokinetics by chemical polysialylation","volume":"19","author":"Constantinou","year":"2008","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2023.115146_b0810","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2021.1940650","article-title":"Inhaled antibodies: Quality and performance considerations","volume":"18","author":"Hickey","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.addr.2023.115146_b0815","doi-asserted-by":"crossref","DOI":"10.1016\/j.xinn.2022.100328","article-title":"Inhalable antibodies for the treatment of COVID-19","volume":"3","author":"Yang","year":"2022","journal-title":"The Innovation."},{"key":"10.1016\/j.addr.2023.115146_b0820","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1007\/s11095-022-03331-w","article-title":"Spray-Dried and Spray-Freeze-Dried Powder Formulations of an Anti-Interleukin-4R\u03b1 Antibody for Pulmonary Delivery","volume":"39","author":"Pan","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2023.115146_b0825","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jconrel.2023.04.029","article-title":"Neutralisation of SARS-CoV-2 by monoclonal antibody through dual targeting powder formulation","volume":"358","author":"Seow","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115146_b0830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/btm2.10391","article-title":"Stable nebulization and muco-trapping properties of regdanvimab\/IN-006 support its development as a potent, dose-saving inhaled therapy for COVID -19","volume":"8","author":"McSweeney","year":"2023","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.addr.2023.115146_b0835","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119291","article-title":"RNA delivery biomaterials for the treatment of genetic and rare diseases","volume":"217","author":"Zhao","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2023.115146_b0840","first-page":"649","article-title":"Gene therapy for cystic fibrosis: recent progress and current aims, Expert Opin Orphan","volume":"4","author":"Paul-Smith","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2023.115146_b0845","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1172\/JCI7935","article-title":"Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus","volume":"104","author":"Harvey","year":"1999","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.addr.2023.115146_b0850","doi-asserted-by":"crossref","first-page":"20210217","DOI":"10.1002\/EXP.20210217","article-title":"mRNA nanomedicine: Design and recent applications","volume":"2","author":"Kubiatowicz","year":"2022","journal-title":"Exploration."},{"key":"10.1016\/j.addr.2023.115146_b0855","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.jconrel.2022.10.061","article-title":"Mechanisms and challenges of nanocarriers as non-viral vectors of therapeutic genes for enhanced pulmonary delivery","volume":"352","author":"Wang","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115146_b0860","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.biotechadv.2019.04.012","article-title":"RNAi therapeutic and its innovative biotechnological evolution","volume":"37","author":"Weng","year":"2019","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.addr.2023.115146_b0865","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1208\/s12248-010-9210-4","article-title":"Delivery of siRNA therapeutics: Barriers and carriers","volume":"12","author":"Wang","year":"2010","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2023.115146_b0870","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.addr.2020.07.022","article-title":"Recent advances in siRNA delivery mediated by lipid-based nanoparticles","volume":"154\u2013155","author":"Yonezawa","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2023.115146_b0875","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.tips.2019.10.009","article-title":"Oligonucleotides to the (Gene) Rescue: FDA Approvals 2017\u20132019","volume":"41","author":"R\u00fcger","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.addr.2023.115146_b0880","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.addr.2023.115146_b0885","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.addr.2020.07.002","article-title":"Liposomes: Advancements and innovation in the manufacturing process","volume":"154\u2013155","author":"Shah","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2023.115146_b0890","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jconrel.2016.05.031","article-title":"Barriers to inhaled gene therapy of obstructive lung diseases: A review","volume":"240","author":"Kim","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115146_b0895","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1038\/mt.2016.182","article-title":"The mucus barrier to inhaled gene therapy","volume":"24","author":"Duncan","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2023.115146_b0900","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1177\/1535370220965985","article-title":"Pulmonary gene delivery\u2014Realities and possibilities","volume":"246","author":"Baliga","year":"2021","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.addr.2023.115146_b0905","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ijpharm.2009.10.023","article-title":"Preparation and characterization of poly(dl-lactide-co-glycolide) nanoparticles for siRNA delivery","volume":"390","author":"Cun","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2023.115146_b0910","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejpb.2010.11.008","article-title":"High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: Quality by design optimization and characterization","volume":"77","author":"Cun","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2023.115146_b0915","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2009.10.010","article-title":"Spray drying of siRNA-containing PLGA nanoparticles intended for inhalation","volume":"142","author":"Jensen","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115146_b0920","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jconrel.2011.08.011","article-title":"Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA","volume":"157","author":"Jensen","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115146_b0925","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1021\/acsami.0c21259","article-title":"Poly(lactide-co-glycolide) Nanoparticles Mediate Sustained Gene Silencing and Improved Biocompatibility of siRNA Delivery Systems in Mouse Lungs after Pulmonary Administration","volume":"13","author":"Wu","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.addr.2023.115146_b0930","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.ymthe.2019.02.019","article-title":"Recent Developments in mRNA-Based Protein Supplementation Therapy to Target Lung Diseases","volume":"27","author":"Sahu","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2023.115146_b0935","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032218","article-title":"Biodrug Delivery Systems: Do mRNA Lipid Nanoparticles Come of Age?","volume":"24","author":"Puccetti","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2023.115146_b0940","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jconrel.2018.10.015","article-title":"PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake","volume":"291","author":"Parhiz","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115146_b0945","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.addr.2007.11.006","article-title":"Targeted delivery of nanoparticles for the treatment of lung diseases","volume":"60","author":"Azarmi","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2023.115146_b0950","doi-asserted-by":"crossref","unstructured":"Y. Qiu, M.Y.-T. Chow, J.K.-W. Lam, Pulmonary Delivery of Messenger RNA (mRNA) Therapeutics for Respiratory Diseases, in: 2022: pp. 139\u2013156. https:\/\/doi.org\/10.1007\/978-3-031-08415-7_7.","DOI":"10.1007\/978-3-031-08415-7_7"},{"key":"10.1016\/j.addr.2023.115146_b0955","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics12111042","article-title":"Aerosolizable lipid nanoparticles for pulmonary delivery of mRNA through design of experiments","volume":"12","author":"Zhang","year":"2020","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.addr.2023.115146_b0960","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jconrel.2019.10.026","article-title":"Effective mRNA pulmonary delivery by dry powder formulation of PEGylated synthetic KL4 peptide","volume":"314","author":"Qiu","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115146_b0965","doi-asserted-by":"crossref","first-page":"8720","DOI":"10.1073\/pnas.1502281112","article-title":"Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy","volume":"112","author":"Mastorakos","year":"2015","journal-title":"PNAS"},{"key":"10.1016\/j.addr.2023.115146_b0970","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1021\/acs.molpharmaceut.8b00502","article-title":"Naked pDNA Inhalation Powder Composed of Hyaluronic Acid Exhibits High Gene Expression in the Lungs","volume":"16","author":"Ito","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2023.115146_b0975","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118880","article-title":"Naked pDNA\/hyaluronic acid powder shows excellent long-term storage stability and gene expression in murine lungs","volume":"574","author":"Ito","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2023.115146_b0980","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.cell.2020.09.040","article-title":"Why and How Vaccines Work","volume":"183","author":"Iwasaki","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.addr.2023.115146_b0985","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1517\/17425247.2013.810622","article-title":"Devices and formulations for pulmonary vaccination","volume":"10","author":"Tonnis","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2023.115146_b0990","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1080\/03639045.2019.1583758","article-title":"Subunit-based mucosal vaccine delivery systems for pulmonary delivery - Are they feasible?","volume":"45","author":"Marasini","year":"2019","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.addr.2023.115146_b0995","article-title":"Nanotechnologies in Delivery of DNA and mRNA Vaccines to the Nasal and Pulmonary Mucosa","volume":"12","author":"Tang","year":"2022","journal-title":"Nanomaterials"},{"key":"10.1016\/j.addr.2023.115146_b1000","author":"Vaghasiya","year":"2020","journal-title":"Overview of the Advantages and Disadvantages of Different Mucosal Sites for the Delivery of Nanoparticles"},{"key":"10.1016\/j.addr.2023.115146_b1005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics11080375","article-title":"Mucosal vaccination via the respiratory tract","volume":"11","author":"Hellfritzsch","year":"2019","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.addr.2023.115146_b1010","first-page":"1","article-title":"Buccal and sublingual vaccines: A review on oral mucosal immunization and delivery systems","volume":"9","author":"Trincado","year":"2021","journal-title":"Vaccines (basel)."},{"key":"10.1016\/j.addr.2023.115146_b1015","article-title":"Rational application of nanoadjuvant for mucosal vaccine delivery system","volume":"481\u2013482","author":"Dewangan","year":"2020","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.addr.2023.115146_b1020","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jconrel.2021.11.002","article-title":"A respirable HPV-L2 dry-powder vaccine with GLA as amphiphilic lubricant and immune-adjuvant","volume":"340","author":"Rossi","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115146_b1025","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1016\/j.vaccine.2005.02.019","article-title":"Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine","volume":"23","author":"Nardelli-Haefliger","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2023.115146_b1030","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1080\/17425247.2022.2131767","article-title":"Are inhaled mRNA vaccines safe and effective?","volume":"19","author":"Jansen","year":"2022","journal-title":"A Review of Preclinical Studies, Expert Opin Drug Deliv."},{"key":"10.1016\/j.addr.2023.115146_b1035","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1183\/09031936.04.00059204","article-title":"Preservation of post-transplant lung function with aerosol cyclosporin","volume":"23","author":"Corcoran","year":"2004","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.addr.2023.115146_b1040","doi-asserted-by":"crossref","first-page":"00167","DOI":"10.1183\/23120541.00167-2019","article-title":"A randomised single-centre trial of inhaled liposomal cyclosporine for bronchiolitis obliterans syndrome post-lung transplantation","volume":"5","author":"Iacono","year":"2019","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.addr.2023.115146_b1045","first-page":"9","article-title":"Capitalizing on the concept of local immune suppression by inhalation for lung transplant recipients","author":"Iacono","year":"2021","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.addr.2023.115146_b1050","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.21037\/jtd.2018.01.46","article-title":"Stem cell therapies for chronic obstructive pulmonary disease: Current status of pre-clinical studies and clinical trials","volume":"10","author":"Sun","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.addr.2023.115146_b1055","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1378\/chest.12-2094","article-title":"A placebo-controlled, randomized trial of mesenchymal stem cells in COPD","volume":"143","author":"Weiss","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.addr.2023.115146_b1060","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/COPD.S15292","article-title":"Unicentric study of cell therapy in chronic obstructive pulmonary disease\/pulmonary emphysema","volume":"6","author":"Ribeiro-Paes","year":"2011","journal-title":"Int. J. COPD"},{"key":"10.1016\/j.addr.2023.115146_b1065","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1039\/C5IB00206K","article-title":"Assessment of the potential of a high frequency acoustomicrofluidic nebulisation platform for inhaled stem cell therapy","volume":"8","author":"Alhasan","year":"2016","journal-title":"Integr. Biol."},{"key":"10.1016\/j.addr.2023.115146_b1070","doi-asserted-by":"crossref","unstructured":"Y. Ventura-Carmenate, F.M. Alkaabi, Y.M. Castillo-Aleman, C.A. Villegas-Valverde, Y.M. Ahmed, P. Sanna, A.A. Almarzooqi, A. Abdelrazik, G.M. Torres-Zambrano, M. Wade-Mateo, D. Quesada-Saliba, L. Abdel Hadi, A.A. Bencomo-Hernandez, R.A. Rivero-Jimenez, Safety and efficacy of autologous non-hematopoietic enriched stem cell nebulization in COVID-19 patients: a randomized clinical trial, Abu Dhabi 2020, Transl Med Commun. 6 (2021). https:\/\/doi.org\/10.1186\/s41231-021-00101-5.","DOI":"10.1186\/s41231-021-00101-5"},{"key":"10.1016\/j.addr.2023.115146_b1075","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1016\/j.celrep.2018.08.090","article-title":"Modulation of Pulmonary Microbiota by Antibiotic or Probiotic Aerosol Therapy: A Strategy to Promote Immunosurveillance against Lung Metastases","volume":"24","author":"Le Noci","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.addr.2023.115146_b1080","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1089\/jamp.2019.1573","article-title":"One-Week Nebulization of Mycobacterium vaccae Can Protect against Pulmonary Respiratory Syncytial Virus Infection in Balb\/c Mice","volume":"33","author":"Jiang","year":"2020","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2023.115146_b1085","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1089\/jamp.2020.1628","article-title":"Mycobacterium vaccae Nebulization in the Treatment of COVID-19: A Randomized, Double-Blind, Placebo-Controlled Trial","volume":"34","author":"Lin","year":"2021","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2023.115146_b1090","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2217\/imt.12.25","article-title":"Therapeutic effects of inhaled inactivated Mycobacterium phlei in adult patients with moderate persistent asthma","volume":"4","author":"Zhang","year":"2012","journal-title":"Immunotherapy"},{"key":"10.1016\/j.addr.2023.115146_b1095","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2217\/imt.12.156","article-title":"Effect of inhaled inactivated Mycobacterium phlei in children with moderate asthma","volume":"5","author":"Ming","year":"2013","journal-title":"Immunotherapy"},{"key":"10.1016\/j.addr.2023.115146_b1100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119177","article-title":"Paclitaxel-in-liposome-in-bacteria for inhalation treatment of primary lung cancer","volume":"578","author":"Zhang","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2023.115146_b1105","year":"2019","journal-title":"FDA Approved Drug Products."},{"key":"10.1016\/j.addr.2023.115146_b1110","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1208\/s12248-008-9044-5","article-title":"Slow release formulations of inhaled rifampin","volume":"10","author":"Coowanitwong","year":"2008","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2023.115146_b1115","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/jgm.1546","article-title":"Sustained inhibition of IL-6 and IL-8 expression by decoy ODN to NF-\u03baB delivered through respirable large porous particles in LPS-stimulated cystic fibrosis bronchial cells","volume":"13","author":"De Stefano","year":"2011","journal-title":"J. Gene Med."},{"key":"10.1016\/j.addr.2023.115146_b1120","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.taap.2006.01.016","article-title":"Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung","volume":"215","author":"Dailey","year":"2006","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.addr.2023.115146_b1125","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ijpharm.2008.03.024","article-title":"A comparative study of a range of polymeric microspheres as potential carriers for the inhalation of proteins","volume":"358","author":"Sivadas","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2023.115146_b1130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2010.03.017","article-title":"Formulation strategy and use of excipients in pulmonary drug delivery","volume":"392","author":"Pilcer","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2023.115146_b1135","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/jbm.a.30421","article-title":"Pulmonary inflammation caused by chitosan microparticles","volume":"75","author":"Huang","year":"2005","journal-title":"J. Biomed. Mater. Res. A"},{"key":"10.1016\/j.addr.2023.115146_b1140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/btm2.10213","article-title":"Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticles","volume":"6","author":"Schlich","year":"2021","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.addr.2023.115146_b1145","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.copbio.2021.10.017","article-title":"Inhalable mRNA vaccines for respiratory diseases: a roadmap","volume":"74","author":"Roh","year":"2022","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.addr.2023.115146_b1150","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ejpb.2017.01.024","article-title":"How sugars protect proteins in the solid state and during drying (review): Mechanisms of stabilization in relation to stress conditions","volume":"114","author":"Mensink","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2023.115146_b1155","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1517\/17425247.2011.553219","article-title":"Stabilization of liposomes during drying","volume":"8","author":"Ingvarsson","year":"2011","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2023.115146_b1160","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jaerosci.2007.04.005","article-title":"Particle formation in spray drying","volume":"38","author":"Vehring","year":"2007","journal-title":"J. Aerosol Sci"},{"key":"10.1016\/j.addr.2023.115146_b1165","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.3109\/03639045.2014.956111","article-title":"Development of dry powder inhaler formulation loaded with alendronate solid lipid nanoparticles: Solid-state characterization and aerosol dispersion performance","volume":"41","author":"Dolatabadi","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.addr.2023.115146_b1170","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ejpb.2014.03.009","article-title":"Spray freeze drying for dry powder inhalation of nanoparticles","volume":"87","author":"Ali","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2023.115146_b1175","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.addr.2006.07.012","article-title":"In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery","volume":"58","author":"Sakagami","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2023.115146_b1180","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ejps.2005.03.010","article-title":"The pharmacokinetics of pulmonary insulin in the in vitro isolated perfused rat lung: Implications of metabolism and regional deposition","volume":"25","author":"Pang","year":"2005","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2023.115146_b1185","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2022.04.061","article-title":"Evaluating the pharmacokinetics of intrapulmonary administered ciprofloxacin solution for respiratory infections using in vivo and in silico PBPK rat model studies","volume":"34","author":"Shi","year":"2023","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.addr.2023.115146_b1190","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.3390\/pharmaceutics15092287","article-title":"In Vitro and In Vivo Evaluation of Inhalable Ciprofloxacin Sustained Release Formulations","volume":"15","author":"Shi","year":"2023","journal-title":"Pharmaceutics."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X23004611?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X23004611?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:44:23Z","timestamp":1759211063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X23004611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":236,"alternative-id":["S0169409X23004611"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2023.115146","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-acting inhaled medicines: Present and future","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2023.115146","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115146"}}